Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Qifeng Zhuo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0248-331X; OpenAlex author ID A5054031774. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2020: 3 papers · 2021: 7 papers · 2022: 2 papers · 2023: none · 2024: 5 papers · 2025: 1 paper

Papers 18

  1. Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41401-025-01477-y↗
  2. Evaluating the efficacy of laparoscopic radical antegrade modular pancreatosplenectomy in selected early-stage left-sided pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-024-10868-x↗
  3. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217197↗
  4. Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1. Co-author DOI 10.1111/cpr.13694↗
  5. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective c… First author DOI 10.1186/s12957-023-03277-2↗
  6. Laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic ductal adenocarcinoma: protocol of a mul… Co-author DOI 10.21203/rs.3.rs-3993645/v1↗
  7. Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Co-author DOI 10.3389/fonc.2022.822039↗
  8. [Effect of laparoscopic surgery for pancreatic cancer after neoadjuvant chemotherapy]. Co-author DOI 10.3760/cma.j.cn112139-20210823-00389↗
  9. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1002/ctm2.398↗
  10. Organoid model: A new hope for pancreatic cancer treatment? First author DOI 10.1016/j.bbcan.2020.188466↗
  11. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Last author DOI 10.1016/j.canlet.2020.11.023↗
  12. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. First author DOI 10.1016/j.redox.2020.101807↗
  13. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Co-author DOI 10.1038/s41401-020-00584-2↗
  14. SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. Co-author DOI 10.1093/abbs/gmab140↗
  15. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-0414↗
  16. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Co-author DOI 10.1038/s41388-020-01452-3↗
  17. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  18. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shunrong Ji · 17 shared papers, 2020–2025 · strength 2.46
  2. Xiaowu Xu · 16 shared papers, 2020–2025 · strength 2.33
  3. Xianjun Yu · 15 shared papers, 2020–2024 · strength 2.17
  4. Wensheng Liu · 12 shared papers, 2020–2024 · strength 1.59
  5. Yi Qin · 10 shared papers, 2020–2025 · strength 1.29
  6. Wenyan Xu · 9 shared papers, 2020–2024 · strength 1.16
  7. Ye Zeng · 8 shared papers, 2020–2022 · strength 0.99
  8. Qiangsheng Hu · 8 shared papers, 2020–2021 · strength 0.87
  9. Mengqi Liu · 6 shared papers, 2020–2024 · strength 0.71
  10. Zheng Zhang · 6 shared papers, 2020–2021 · strength 0.63
  11. Borui Li · 3 shared papers, 2024–2025 · strength 0.58
  12. Chenjie Zhou · 3 shared papers, 2024–2025 · strength 0.58
  13. Zheng Li · 3 shared papers, 2022–2025 · strength 0.55
  14. Chenjie Zhou · 2 shared papers, 2024 · strength 0.38
  15. Haidi Chen · 2 shared papers, 2021–2024 · strength 0.35
  16. Ye Zeng · 3 shared papers, 2021 · strength 0.34
  17. Heli Gao · 2 shared papers, 2022–2024 · strength 0.33
  18. Xiaowu Xu · 2 shared papers, 2022–2024 · strength 0.33
  19. Mengqi Liu · 2 shared papers, 2021–2024 · strength 0.32
  20. Qiqing Sun · 3 shared papers, 2020 · strength 0.29
  21. Di Wu · 1 shared paper, 2025 · strength 0.21
  22. Zheng Li · 1 shared paper, 2024 · strength 0.20
  23. Faliang Xing · 1 shared paper, 2024 · strength 0.20
  24. Chen Chen · 1 shared paper, 2024 · strength 0.20
  25. Zheng Li · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.